Transgene Reports Business Update and End Q1 2021 Financial Position - Seite 2

✓ Trial ongoing in the United Kingdom and in France

✓ First patient treated in Jan. 2021 – Inclusions and patient dosing progressing
in line with forecast

➲ First data expected in 4Q 2021

TG4001 + avelumab Phase II NCT03260023

Targets: HPV16 E6 and E7 oncoproteins Recurrent/metastatic anogenital HPV-positive – 1st and 2nd line ✓ A Phase II randomized trial comparing the efficacy of TG4001 + avelumab versus avelumab single-agent benefits from the extended clinical collaboration with Merck KGaA and Pfizer, for the supply of avelumab ✓ Regulatory authorizations received in the Unites States, Spain, and France ➲ Patient enrollment in the randomized trial expected to start in 2Q 2021 ➲ First data from the randomized trial are expected around the end of 2022. This timeline is based on patient enrollment starting in 2Q 2021 and there being no major impact on recruitment from the Covid-19 pandemic.

Invir.IO BT-001 Phase I/IIa   NCT04725331

Payload: anti-CTLA4 antibody and GM-CSF cytokine Solid tumors ✓ Co-development with BioInvent ✓ Trial ongoing in France and Belgium ✓ First patient enrolled in February 2021 – Inclusions and patient dosing progressing in line with forecast ➲ US IND expected in 2021 ➲ First Phase I data expected in 1H 2022

TG6002 Phase I/IIa NCT03724071	Payload: FCU1 for the local production of a 5-FU chemotherapy Gastro-intestinal cancer (colorectal cancer for Phase II) – Intravenous (IV) administration ✓ Multicenter trial ongoing in Belgium, France and Spain ✓ Poster presentation at AACR 2021 on initial data of the trial, demonstrating the clinical proof of concept of the intravenous route of administration ➲ Phase I part ongoing
TG6002